

06-26-00

A

PATENT  
Attorney Docket No. MEDIN1400

06/23/00  
J-687 U.S. PTO

- ☒ NEW PATENT APPLICATION  
☐ CONTINUATION-IN-PART  
☐ DIVISIONAL

ASSISTANT COMMISSIONER  
FOR PATENTS  
Box Patent Application  
Washington, D.C. 20231

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

"EXPRESS MAIL" MAILING LABEL NO. **EL617040291US**

DATE OF DEPOSIT 06/23/2000 I HEREBY CERTIFY  
THAT THIS PAPER OR FEE IS BEING DEPOSITED WITH THE UNITED STATES  
POSTAL SERVICE "EXPRESS MAIL POST OFFICE TO ADDRESSEE" SERVICE  
UNDER 37 C.F.R. 1.10 ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO  
THE ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231

Michael Bayley  
(TYPED OR PRINTED NAME OF PERSON MAILING PAPER OR FEE)

Michael Bayley  
SIGNATURE OF PERSON MAILING PAPER OR FEE

06/23/00  
J-687 U.S. PTO

Sir:

Transmitted herewith for filing is the new patent application of

Inventor(s): Ching-San Lai and Tingmin Wang

For: **PROTECTED FORMS OF PHARMACOLOGICALLY ACTIVE AGENTS AND USES  
THEREFOR**

Enclosed are:

- ☒ 44 pages of the Specification, which includes 6 pages of the claims.  
☒ 1 page of the Abstract;  
☒ 3 sheets of drawing(s) ☒ Formal; ☐ Informal;  
☒ A Declaration;  
☒ Power of Attorney By Assignee;  
☒ An assignment of the invention with cover sheet to MEDINOX, INC.; and  
☒ A verified statement to establish small entity status under 37 C.F.R. 1.9 and 37 C.F.R. 1.27.

FULL NAME OF FIRST INVENTOR	LAST NAME: <b>Lai</b>	FIRST NAME: <b>Ching-San</b>	MIDDLE NAME: <b>None</b>
CITIZENSHIP	STATE OR FOREIGN COUNTRY: <b>United States</b>		
POST OFFICE ADDRESS	POST OFFICE ADDRESS: <b>209 Lolita Street</b>	CITY AND STATE: <b>Encinitas, CA</b>	ZIP CODE: <b>92024</b>
FULL NAME OF SECOND INVENTOR	LAST NAME: <b>Wang</b>	FIRST NAME: <b>Tingmin</b>	MIDDLE NAME: <b>None</b>
CITIZENSHIP	STATE OR FOREIGN COUNTRY: <b>People's Republic of China</b>		
POST OFFICE ADDRESS	POST OFFICE ADDRESS: <b>585 Sonoma Street</b>	CITY AND STATE: <b>San Marcos, CA</b>	ZIP CODE: <b>92069</b>

In re Application of:  
Lai and Wang  
Application No.: unassigned  
Filed: June 23, 2000  
Page 2

PATENT  
Attorney Docket No.: MEDIN1400

The filing fee has been calculated as shown below:

For	Number Filed		Number Extra	Rate		Fee	
				Small Entity	Other Entity	Small Entity	Other Entity
Total Claims	33	=	13	\$9	\$18	=	\$117.00 \$ 0
Independent Claims	7	=	4	\$39	\$78	=	\$156.00 0
Multiple Dependent Claims Presented: <u>  </u> Yes <u>  X  </u> No  BASIC FEE				\$130	\$260		0
				\$345	\$690	\$345.00	\$ 0
				TOTAL FEE		\$618.00	\$ 0

☐ The payment of the filing fee is to be deferred until the Declaration is filed. Do not charge our deposit account.

☒ The Commissioner is authorized to charge payment in the amount of \$658.00; \$345.00 for the filing fee, \$273.00 for the additional independent claims and \$40.00 for the recordation of one (1) assignment and any other fees associated with this communication or credit any overpayment to Deposit Account No. 07-1895. A duplicate copy of this sheet is enclosed.


☒ Any additional filing fees required under 37 C.F.R. 1.16.

☒ Any patent application processing fees under 37 C.F.R. 1.17.

Respectfully submitted,

Date:

6/23/00

  
Stephen E. Reiter  
Attorney for Applicant  
Registration No. 31,192  
Telephone: 858-677-1409  
Facsimile: 858-677-1465

GRAY CARY WARE & FREIDENRICH LLP  
4365 Executive Drive, Suite 1600  
San Diego, CA 92121-2189

Attorney Docket No. MEDIN1400  
Applicant or Patentee: Lai and Wang  
Serial No. or Patent No.:  
Filed or Issued: June 23, 2000  
Title: PROTECTED FORMS OF PHARMACOLOGICALLY ACTIVE AGENTS AND USES  
THEREFOR

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS  
(37 C.F.R. §§ 1.9(f) and 1.27(c)) - SMALL BUSINESS CONCERN**

I hereby declare that I am

- ☐ the owner of the small business concern identified below:  
☒ an official of the small business concern empowered to act on behalf of the concern identified below:

NAME OF CONCERN MEDINOX, INC.

ADDRESS OF CONCERN 11575 Sorrento Valley Road, Suite 201  
San Diego, California 92121

I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 13 C.F.R. §121.3-18 and reproduced in 37 C.F.R. § 1.9(d), for purposes of paying reduced fees under Section 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention, entitled **PROTECTED FORMS OF PHARMACOLOGICALLY ACTIVE AGENTS AND USES THEREFOR** by inventors **Ching-San Lai and Tingmin Wang** described in:

- ☒ the specification filed herewith  
☐ Based on Application Serial No. \_\_\_\_\_, filed herewith.  
☐ Patent No. \_\_\_\_\_, issued \_\_\_\_\_

I authorize and request insertion of the serial number of the application when officially known.

I hereby declare that rights under contract or law have been conveyed to and remain with the nonprofit organization with regard to the above-identified invention.

If the rights held by the above identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below and no rights to the invention are held by any person, other than the inventor, who could not qualify as a small business concern under 37 C.F.R. § 1.9(d) or by any concern which would not qualify as a small business concern under 37 C.F.R. § 1.9(d) or a nonprofit organization under 37 C.F.R. § 1.9(e).

**NOTE:** Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities (37 C.F.R. § 1.27).

Full Name \_\_\_\_\_

Address \_\_\_\_\_

☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

Full Name \_\_\_\_\_

Address \_\_\_\_\_

☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate (37 C.F.R. § 1.28(b)).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING Ching-San Lai

TITLE OF PERSON OTHER THAN OWNER President and Chief Executive Officer

ADDRESS OF PERSON SIGNING \_\_\_\_\_

SIGNATURE [Signature] DATE 6/23/00

## \*EXPRESS MAIL LABEL NUMBER

DATE OF DEPOSIT

06/23/2000

(TYPE OR PRINTED NAME OF PERSON MAILING PAPER)

(SIGNATURE OF PERSON MAILING PAPER OR FEE)

Gray Cary Ware & Freidenrich  
4365 Executive Drive, Suite 1600  
San Diego, California 92121-2189

[illegible]

Protected Forms of Pharmacologically  
Active Agents and Uses Therefor

FIELD OF THE INVENTION

5 The present invention relates to novel forms of pharmacologically active agents, and methods for the preparation and use thereof. In a particular aspect of the invention, methods are provided for treating pathological conditions with a protected form of one or more pharmacologically active agents, thereby reducing the occurrence of side-effects caused thereby.

BACKGROUND OF THE INVENTION

10 Despite the advent of modern pharmaceutical technology, many drugs still possess untoward toxicities which often limit the therapeutic potential thereof. For example, although non-steroid anti-inflammatory drugs (NSAIDs) are a class of compounds which are widely used for the treatment of inflammation, pain and fever, NSAIDs (e.g., naproxen, aspirin, ibuprofen and ketoprofen) can cause gastrointestinal ulcers, a side-effect that remains the major limitation to the use of NSAIDs (see, for example, J. L. Wallace, in Gastroenterol. 112:1000-1016 (1997); A. H. Soll et al., in Ann Intern Med. 114:307-319 (1991); and J. Bjarnason et al., in Gastroenterol. 104:1832-1847 (1993)).

20 There are two major ulcerogenic effects of NSAIDs: (1) irritant effects on the epithelium of the gastrointestinal tract and (2) suppression of gastrointestinal prostaglandin synthesis. In recent years, numerous strategies have been attempted to design and develop new NSAIDs that reduce the damage to the gastrointestinal tract. These efforts, however, have largely been unsuccessful. For example, enteric coating or slow-release formulations designed to reduce the topical irritant properties of NSAIDs have been shown to be ineffective in terms of reducing the incidence of clinically significant side effects, including perforation and bleeding (see, for example, D. Y.

Graham et al., in Clin. Pharmacol. Ther. 38:65-70 (1985); and J. L. Carson, et al., in Arch. Intern. Med., 147:1054-1059 (1987)).

It is well recognized that aspirin and other NSAIDs exert their pharmacological effects through the non-selective inhibition of cyclooxygenase (COX) enzymes, thereby blocking prostaglandin synthesis (see, for example, J. R. Van in Nature, 231:232-235 (1971)). There are two types of COX enzymes, namely COX-1 and COX-2. COX-1 is expressed constitutively in many tissues, including the stomach, kidney, and platelets, whereas COX-2 is expressed only at the site of inflammation (see, for example, S. Kargan et al. in Gastroenterol., 111:445-454 (1996)). The prostaglandins derived from COX-1 are responsible for many of the physiological effects, including maintenance of gastric mucosal integrity.

Many attempts have been made to develop NSAIDs that only inhibit COX-2, without impacting the activity of COX-1 (see, for example, J.A. Mitchell et al., in Proc. Natl. Acad. Sci. USA 90:11693-11697 (1993); and E.A. Meade et al., in J. Biol. Chem., 268:6610-6614 (1993)). There are several NSAIDs presently on the market (e.g., rofecoxib and celecoxib) that show marked selectivity for COX-2 (see, for example, E. A. Meade, supra; K. Glaser et al., in Eur. J. Pharmacol. 281:107-111 (1995) and Kaplan-Machlis, B., and Klostermeyer, BS in Ann Pharmacother. 33:979-88, (1999)). These drugs appear to have reduced gastrointestinal toxicity relative to other NSAIDs on the market.

On the basis of encouraging clinical as well as experimental data, the development of highly selective COX-2 inhibitors appears to be a sound strategy to develop a new generation of anti-inflammatory drugs. However, the physiological functions of COX-1 and COX-2 are not always well defined. Thus, there is a possibility that prostaglandins produced as a result of COX-1 expression may also contribute to inflammation, pain and fever. On the other hand, prostaglandins produced by COX-2 have been shown to play important physiological functions, including the initiation and maintenance of labor and in the regulation of bone resorption (see, for example, D. M.

Slater et al., in Am. J. Obstet. Gynecol., 172:77-82 (1995); and Y. Onoe et al., in J. Immunol. 156:758-764 (1996)), thus inhibition of this pathway may not always be beneficial. Considering these points, highly selective COX-2 inhibitors may produce additional side effects above and beyond those observed with standard NSAIDs, therefore such inhibitors may not be highly desirable.

Accordingly, there is still a need in the art for modified forms of NSAIDs which cause a reduced incidence of side-effects, relative to the incidence of side-effects caused by such pharmacologically active agents in unmodified form.

#### BRIEF DESCRIPTION OF THE INVENTION

In accordance with the present invention, there is provided a new class of modified NSAIDs which cause a much lower incidence of side-effects than are typically observed with unmodified NSAIDs due to the protective effects imparted by modifying the NSAIDs as described herein.

There are a number of advantages provided by modified NSAIDs according to the invention including:

- (i) reduced irritant effects (e.g., contact irritation) of NSAIDs, and
- (ii) enhanced tissue delivery of the drug as a result of a decrease in net charges on the molecule, particularly for acidic NSAIDs such as naproxen, aspirin, diclofenac and ibuprofen, thereby reducing the quantity of material which must be delivered to achieve an effective dosage.

In accordance with the present invention, cleavage of the modified NSAIDs described herein from the modified group appended thereto releases the pharmaceutically active agent.

### BRIEF DESCRIPTION OF THE FIGURES

Figure 1 illustrates the total length of intestinal ulcers measured after three daily doses of NSAID in unfasted male Sprague-Dawley rats (150-200 g) treated with vehicle, naproxen or equimolar invention composition (compound 19). \*  $P < 0.05$  by unpaired t-test.

Figure 2 illustrates the total length of intestinal ulcers measured after 14 daily doses of NSAID in unfasted male Sprague-Dawley rats (150-200 g) treated with vehicle (bar 7), three doses of naproxen (bar 1: 50 mg/kg, bar 2: 45 mg/kg, bar 3: 40 mg/kg), or three equimolar doses of invention composition (compound 19) (bars 4-6). \*  $P < 0.05$  by unpaired t-test vs. corresponding dose of naproxen.

Figure 3 illustrates the inhibition of paw volume increases in the uninjected feet of Lewis male rats in which arthritis was induced by intradermal injection of adjuvant into the footpad. Rats were injected on day 0 and treated once daily from days 8 to 15 with vehicle, naproxen (10 mg/kg), or invention composition (compound 19) at equivalent dose. Paw volumes were measured with a Plethysmometer on days 5 and 15. Closed circles = naproxen; squares = invention composition.

### DETAILED DESCRIPTION OF THE INVENTION

In accordance with the present invention, there are provided compounds comprising a modified NSAID, wherein the NSAID is covalently attached either directly or through a linker molecule to a sulfur-containing functional group containing an optionally substituted hydrocarbyl moiety. Invention compounds have the structure:

X-L-Z



wherein:

X = a non-steroidal anti-inflammatory drug (NSAID),

L = an optional linker/spacer, and

5 Z = a sulfur-containing functional group containing an optionally substituted hydrocarbyl moiety.

NSAIDs contemplated for modification in accordance with the present invention include acetaminophen (Tylenol, Datril, etc.), aspirin, ibuprofen (Motrin, Advil, Rufen, 10 others), choline magnesium salicylate (Triasate), choline salicylate (Anthropan), diclofenac (voltaren, cataflam), diflunisal (dolobid), etodolac (Iodine), fenoprofen calcium (nalfon), flurbiprofen (ansaid), indomethacin (indocin, indometh, others), ketoprofen (orudis, oruvail), carprofen, indoprofen, ketorolac tromethamine (toradol), magnesium salicylate (Doan's, magan, mobidin, others), meclofenamate sodium 15 (meclomen), mefenamic acid (relafan), oxaprozin (daypro), piroxicam (feldene), sodium salicylate, sulindac (clinoril), tolmetin (tolectin), meloxicam, nabumetone, naproxen, lornoxicam, nimesulide, indoprofen, remifenzone, salsalate, tiaprofenic acid, flosulide, and the like. Presently preferred NSAIDs employed in the practice of the invention include naproxen, aspirin, ibuprofen, flurbiprofen, indomethacin, ketoprofen, carprofen, 20 and the like.

Invention compounds can be readily prepared in a variety of ways either by direct reaction of NSAIDs with the sulfur-containing functional group or indirectly through a suitable linker molecule.

25 The components of invention compositions are directly or indirectly covalently attached employing a variety of linkages (including an optional linker), e.g., ester linkages, disulfide linkages, amide linkages, immine linkages, enamine linkages, ether linkages, thioether linkages, imide linkages, sulfate ester linkages, sulfonate ester 30 linkages, sulfone linkages, sulfonamide linkages, phosphate ester linkages, carbonate linkages, O-glycosidic linkages, S-glycosidic linkages, and the like. Such linkages can

be accomplished using standard synthetic techniques as are well known by those of skill in the art, either by direct reaction of the starting materials, or by incorporating a suitable functional group on the starting material, followed by coupling of the reactants.

5           When the pharmacologically active agents contemplated for use herein contain suitable functionality thereon, e.g., hydroxy, amino, carboxy, and the like, invention modified NSAIDs can be prepared by direct linkage between the two agents. Alternatively, the NSAIDs can be functionalized so as to facilitate linkage between the two agents. When present, linker/spacer L has the following structure:

10                               -W-R-

                              wherein:


                              R is optional, and when present is alkylene, substituted alkylene, cycloalkylene, substituted cycloalkylene, heterocyclic, substituted heterocyclic, oxyalkylene, substituted oxyalkylene, alkenylene, substituted alkenylene, arylene, 15           substituted arylene, alkarylene, substituted alkarylene, aralkylene or substituted aralkylene, and

                              W is ester, reverse ester, thioester, reverse thioester, amide, reverse amide, phosphate, phosphonate, imine, enamine, or the like.

20           Functional groups contemplated by the present invention are sulfur-based. Examples of suitable sulfur-containing functional groups include sulfonate, reverse sulfonate, sulfonamide, reverse sulfonamide, sulfone, sulfinatate, reverse sulfinatate, and the like. In a particular aspect of the invention, the sulfur-based moiety is sulfonate or reverse sulfonate. In a particularly preferred aspect of the invention, the sulfonate is an 25           optionally substituted aromatic sulfonate such as tosylate or brosylate.

                              Other preferred sulfur-based functional groups contemplated by the present invention include sulfones. Preferably, the sulfone is an optionally substituted alkyl or aromatic sulfone.

In one aspect of the invention, Z may have the following structure:



wherein:

each of Y and Y' are optionally present, and when present are independently -O- or -NR'-, wherein R' is H or an optionally substituted hydrocarbyl moiety;

n is 1 or 2, and

Q is H or an optionally substituted hydrocarbyl moiety.

As employed herein, "hydrocarbyl" embraces alkyl, substituted alkyl, oxyalkyl, substituted oxyalkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, monocyclic heterocyclic, substituted monocyclic heterocyclic, monocyclic aromatic, monosubstituted monocyclic aromatic, or the like.

As employed herein, "alkyl" refers to hydrocarbyl radicals having 1 up to 20 carbon atoms, preferably 2-10 carbon atoms; and "substituted alkyl" comprises alkyl groups further bearing one or more substituents selected from hydroxy, alkoxy (of a lower alkyl group), mercapto (of a lower alkyl group), cycloalkyl, substituted cycloalkyl, heterocyclic, substituted heterocyclic, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aryloxy, substituted aryloxy, halogen, trifluoromethyl, cyano, nitro, nitron, amino, amido, -C(O)H, acyl, oxyacyl, carboxyl, carbamate, sulfonyl, sulfonamide, sulfuryl, and the like.

As employed herein, "oxyalkyl" refers to the moiety -O-alkyl-, wherein alkyl is as defined above, and "substituted oxyalkyl" refers to oxyalkyl groups further bearing one or more substituents as set forth above.

As employed herein, "cycloalkyl" refers to cyclic ring-containing groups containing in the range of about 3 up to 8 carbon atoms, and "substituted cycloalkyl" refers to cycloalkyl groups further bearing one or more substituents as set forth above.

As employed herein, "heterocyclic" refers to cyclic (i.e., ring-containing) groups containing one or more heteroatoms (e.g., N, O, S, or the like) as part of the ring structure, and having in the range of 3 up to 14 carbon atoms and "substituted  
5 heterocyclic" refers to heterocyclic groups further bearing one or more substituents as set forth above.

As employed herein, "alkenyl" refers to straight or branched chain hydrocarbonyl groups having at least one carbon-carbon double bond, and having in the range of about  
10 2 up to 12 carbon atoms, and "substituted alkenyl" refers to alkenyl groups further bearing one or more substituents as set forth above.

As employed herein, "alkynyl" refers to straight or branched chain hydrocarbonyl groups having at least one carbon-carbon triple bond, and having in the range of about 2  
15 up to 12 carbon atoms, and "substituted alkynyl" refers to alkynylene groups further bearing one or more substituents as set forth above.

As employed herein, "monocyclic aromatic" refers to aromatic groups having in the range of 5 up to 7 carbon atoms and "monosubstituted monocyclic aromatic" refers  
20 to aromatic groups further bearing one of the substituents set forth above.

As employed herein, "alkylene" refers to divalent hydrocarbonyl radicals having 1 up to 20 carbon atoms, preferably 2-10 carbon atoms; and "substituted alkylene"  
25 comprises alkylene groups further bearing one or more substituents as set forth above.

As employed herein, "cycloalkylene" refers to cyclic ring-containing groups containing in the range of about 3 up to 8 carbon atoms, and "substituted cycloalkylene"  
refers to cycloalkylene groups further bearing one or more substituents as set forth above.

As employed herein, "oxyalkylene" refers to the moiety -O-alkylene-, wherein alkylene is as defined above, and "substituted oxyalkylene" refers to oxyalkylene groups further bearing one or more substituents as set forth above.

5

As employed herein, "alkenylene" refers to divalent, straight or branched chain hydrocarbyl groups having at least one carbon-carbon double bond, and having in the range of about 2 up to 12 carbon atoms, and "substituted alkenylene" refers to alkenylene groups further bearing one or more substituents as set forth above.

10

As employed herein, "alkynylene" refers to divalent straight or branched chain hydrocarbyl groups having at least one carbon-carbon triple bond, and having in the range of about 2 up to 12 carbon atoms, and "substituted alkynylene" refers to alkynylene groups further bearing one or more substituents as set forth above.

15

As employed herein, "arylene" refers to divalent aromatic groups having in the range of 6 up to 14 carbon atoms and "substituted arylene" refers to arylene groups further bearing one or more substituents as set forth above.

20

As employed herein, "alkylarylene" refers to alkyl-substituted arylene groups and "substituted alkylarylene" refers to alkylarylene groups further bearing one or more substituents as set forth above.

25

As employed herein, "arylalkylene" refers to aryl-substituted alkylene groups and "substituted arylalkylene" refers to arylalkylene groups further bearing one or more substituents as set forth above.

30

As employed herein, "arylalkenylene" refers to aryl-substituted alkenylene groups and "substituted arylalkenylene" refers to arylalkenylene groups further bearing one or more substituents as set forth above.



As employed herein, "arylkynylene" refers to aryl-substituted alkynylene groups and "substituted arylalkynylene" refers to arylalkynylene groups further bearing one or more substituents as set forth above.

5 Diseases and conditions contemplated for treatment in accordance with the present invention include inflammatory and infectious diseases, such as, for example, septic shock, hemorrhagic shock, anaphylactic shock, toxic shock syndrome, ischemia, cerebral ischemia, administration of cytokines, overexpression of cytokines, ulcers, inflammatory bowel disease (e.g., ulcerative colitis or Crohn's disease), diabetes, 10 arthritis, asthma, Alzheimer's disease, Parkinson's disease, multiple sclerosis, cirrhosis, allograft rejection, encephalomyelitis, meningitis, pancreatitis, peritonitis, vasculitis, lymphocytic choriomeningitis, glomerulonephritis, uveitis, ileitis, inflammation (e.g., liver inflammation, renal inflammation, and the like), burn, infection (including bacterial, viral, fungal and parasitic infections), hemodialysis, chronic fatigue syndrome, 15 stroke, cancers (e.g., breast, melanoma, carcinoma, and the like), cardiopulmonary bypass, ischemic/reperfusion injury, gastritis, adult respiratory distress syndrome, cachexia, myocarditis, autoimmune disorders, eczema, psoriasis, heart failure, heart disease, atherosclerosis, dermatitis, urticaria, systemic lupus erythematosus, AIDS, AIDS dementia, chronic neurodegenerative disease, chronic pain, priapism, cystic 20 fibrosis, amyotrophic lateral sclerosis, schizophrenia, depression, premenstrual syndrome, anxiety, addiction, migraine, Huntington's disease, epilepsy, neurodegenerative disorders, gastrointestinal motility disorders, obesity, hyperphagia, solid tumors (e.g., neuroblastoma), malaria, hematologic cancers, myelofibrosis, lung injury, graft-versus-host disease, head injury, CNS trauma, hepatitis, renal failure, liver 25 disease (e.g., chronic hepatitis C), drug-induced lung injury (e.g., paraquat), myasthenia gravis (MG), ophthalmic diseases, post-angioplasty, restenosis, angina, coronary artery disease, and the like.

In accordance with another embodiment of the present invention, there are 30 provided methods for the preparation of modified NSAIDs, said method comprising covalently attaching a NSAID to a sulfur-containing functional group containing an

optionally substituted hydrocarbyl moiety. The resulting compound provides a latent form of the pharmacologically active agent, releasing the biological activity thereof only when the compound is cleaved (e.g., by an esterase, amidase or other suitable enzyme).

5 As readily recognized by those of skill in the art, invention compounds can be prepared in a variety of ways. See, for example, Scheme 1, wherein NSAID, **X**, bearing a carboxylic moiety can be reacted either directly with the sulfur-containing functional group (Scheme 1a) or indirectly through a linker molecule (Scheme 1b).

10 **Scheme 1a****Scheme 1b**

Employing these general reaction schemes, invention modified NSAIDs can be prepared from a wide variety of pharmacologically active agents. See, for example, Examples 1-29 provided herein.

15

In accordance with yet another embodiment of the present invention, there are provided methods for reducing the side effects induced by administration of NSAIDs to a subject, said method comprising covalently attaching a sulfur-containing functional group containing an optionally substituted hydrocarbyl moiety to said NSAID prior to  
 20 administration to said subject.

In accordance with still another embodiment of the present invention, there are provided methods for enhancing the effectiveness of NSAIDs, said method comprising covalently attaching a sulfur-containing functional group containing an optionally substituted hydrocarbyl moiety to said NSAID.

5

In accordance with a still further embodiment of the present invention, there are provided improved methods for the administration of NSAIDs to a subject for the treatment of a pathological condition, the improvement comprising covalently attaching said NSAID to a sulfur-containing functional group containing an optionally substituted hydrocarbyl moiety prior to administration thereof to said subject.

10

Those of skill in the art recognize that the modified NSAIDs described herein can be delivered in a variety of ways, such as, for example, orally, intravenously, subcutaneously, parenterally, rectally, by inhalation, and the like.

15

Depending on the mode of delivery employed, the modified NSAIDs contemplated for use herein can be delivered in a variety of pharmaceutically acceptable forms. For example, the invention modified NSAIDs can be delivered in the form of a solid, solution, emulsion, dispersion, micelle, liposome, and the like.

20

Thus, in accordance with still another embodiment of the present invention, there are provided physiologically active composition(s) comprising invention modified NSAIDs in a suitable vehicle rendering said compounds amenable to oral delivery, transdermal delivery, intravenous delivery, intramuscular delivery, topical delivery, nasal delivery, and the like.

25

Pharmaceutical compositions of the present invention can be used in the form of a solid, a solution, an emulsion, a dispersion, a micelle, a liposome, and the like, wherein the resulting composition contains one or more of the modified NSAIDs of the present invention, as an active ingredient, in admixture with an organic or inorganic carrier or excipient suitable for enteral or parenteral applications. Invention modified

30



NSAIDs may be compounded, for example, with the usual non-toxic, pharmaceutically acceptable carriers for tablets, pellets, capsules, suppositories, solutions, emulsions, suspensions, and any other form suitable for use. The carriers which can be used include glucose, lactose, gum acacia, gelatin, mannitol, starch paste, magnesium trisilicate, talc, corn starch, keratin, colloidal silica, potato starch, urea, medium chain length triglycerides, dextrans, and other carriers suitable for use in manufacturing preparations, in solid, semisolid, or liquid form. In addition auxiliary, stabilizing, thickening and coloring agents and perfumes may be used. Invention modified NSAIDs are included in the pharmaceutical composition in an amount sufficient to produce the desired effect upon the process or disease condition.

Pharmaceutical compositions containing invention modified NSAIDs may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of a sweetening agent such as sucrose, lactose, or saccharin, flavoring agents such as peppermint, oil of wintergreen or cherry, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets containing invention modified NSAIDs in admixture with non-toxic pharmaceutically acceptable excipients may also be manufactured by known methods. The excipients used may be, for example, (1) inert diluents such as calcium carbonate, lactose, calcium phosphate or sodium phosphate; (2) granulating and disintegrating agents such as corn starch, potato starch or alginic acid; (3) binding agents such as gum tragacanth, corn starch, gelatin or acacia, and (4) lubricating agents such as magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the techniques described in the U.S. Pat. Nos. 4,256,108; 4,160,452; and 4,265,874, to form

osmotic therapeutic tablets for controlled release.

In some cases, formulations for oral use may be in the form of hard gelatin capsules wherein the invention modified NSAIDs are mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin. They may also be in the form of soft gelatin capsules wherein the invention modified NSAIDs are mixed with water or an oil medium, for example, peanut oil, liquid paraffin, or olive oil.

The pharmaceutical compositions may be in the form of a sterile injectable suspension. This suspension may be formulated according to known methods using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides, fatty acids (including oleic acid), naturally occurring vegetable oils like sesame oil, coconut oil, peanut oil, cottonseed oil, etc., or synthetic fatty vehicles like ethyl oleate or the like. Buffers, preservatives, antioxidants, and the like can be incorporated as required.

Invention modified NSAIDs contemplated for use in the practice of the present invention may also be administered in the form of suppositories for rectal administration of the drug. These compositions may be prepared by mixing the invention modified NSAIDs with a suitable non-irritating excipient, such as cocoa butter, synthetic glyceride esters of polyethylene glycols, which are solid at ordinary temperatures, but liquify and/or dissolve in the rectal cavity to release the drug.

Since individual subjects may present a wide variation in severity of symptoms and each drug has its unique therapeutic characteristics, the precise mode of administration and dosage employed for each subject is left to the discretion of the practitioner.

In general, the dosage of invention modified NSAIDs employed as described herein falls in the range of about 0.01 mmoles/kg body weight of the subject/hour up to about 0.5 mmoles/kg/hr. Typical daily doses, in general, lie within the range of from about 10  $\mu$ g up to about 100 mg per kg body weight, and, preferably within the range of from 50  $\mu$ g to 10 mg per kg body weight and can be administered up to four times daily. The daily IV dose lies within the range of from about 1  $\mu$ g to about 100 mg per kg body weight, and, preferably, within the range of from 10  $\mu$ g to 10 mg per kg body weight.

In accordance with yet another embodiment of the present invention, there are provided improved methods for the treatment of a subject suffering from a pathological condition by administration thereto of a NSAID, the improvement comprising covalently attaching said NSAID to a sulfur-containing functional group containing an optionally substituted hydrocarbyl moiety prior to administration thereof to said subject.

Thus, invention method for the treatment of a subject afflicted with a pathological condition comprises administering to a subject an effective amount of a modified pharmacologically active agent,


wherein said pharmacologically active agent is a NSAID, and is effective for treatment of said condition, and

wherein said pharmacologically active agent has been modified by the covalent attachment thereto of a sulfur-containing functional group containing an optionally substituted hydrocarbyl moiety.

The invention will now be described in greater detail by reference to the following non-limiting examples.

The syntheses described in Examples 1-8 are outlined in Scheme 2.

Scheme 2



### Example 1

**Compound 10** (Scheme 2). A mixture of Naproxen (**1**) (23 g, 0.1 mol), ethylene glycol (**2**) (27.9 ml, 0.5 mol) and toluenesulfonic acid (TsOH) (1.27g, 6.7 mmol) in  $\text{CHCl}_3$  was heated to reflux for 4 h. The reaction solution was washed with water, 10%  $\text{Na}_2\text{CO}_3$  solution and water. The organic layer was dried ( $\text{Na}_2\text{SO}_4$ ) and the solvent was evaporated. The residue was purified by crystallization from  $\text{CH}_2\text{Cl}_2$  and hexanes to give 25.7g (94%) of the compound **10** as a white crystal ;  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.59 (d, 3H), 1.62 (br, 1H, ex  $\text{D}_2\text{O}$ ), 3.74 (t, 2H), 3.90 (q, 1H), 3.91 (s, 3H), 4.21 (t, 2H), 7.11 (m, 2H), 7.39 (d, 1H), 7.69 (m, 3H);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  18.7, 45.6, 55.5, 61.4, 66.6, 105.8, 119.3, 126.1, 126.2, 127.5, 129.1, 129.5, 133.9, 135.7, 157.9, 175.2; MS (ESI)  $m/z$  273 (M-1).

**Compound 18** (Scheme 2). To a solution of compound **10** (24.5g, 89 mmol) in 100 ml of pyridine was added tosyl chloride (TsCl) (34.1g, 179 mmol). The resulting solution was stirred at  $0^\circ\text{C}$  for 2.5h. The reaction solution was then poured into 300 ml of water and then 200 ml of ether was added. The layers were separated and the organic phase was washed with water (300 x 5) and dried ( $\text{Na}_2\text{SO}_4$ ). After the solvent was evaporated, the residue was purified by column chromatography on a silica gel column using dichloromethane as an eluent to give 35.1g ( 92%) of the pale yellow oil;  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.55(d, 3H), 2.40 (s, 3H), 3.91 (q, 1H), 4.18 (m, 4H), 7.12 (m, 2H), 7.24 (m, 2H), 7.37 (d, 1H), 7.66 (d, 1H), 7.70 (m, 4H); MS (ESI)  $m/z$  429 (M+1).

### Example 2

**Compound 11** (Scheme 2). Compound **11** was prepared as described above for the preparation of compound **10**, this time employing naproxen (**1**) and 1,3-propanediol (**3**). The resulting compound **11** was purified by crystallization from dichloromethane and hexanes with a 92% yield.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.59 (d, 3H), 1.78 (m, 2H), 1.87 (br, 1H,  $\text{D}_2\text{O}$  ex), 3.53 (t, 2H), 3.87 (q, 1H), 3.91 (s, 3H), 4.23 (t, 2H),

5

10

15

## 20

25

**Compound 20** (Scheme 2). Compound **20** was prepared as described above for the preparation of compound **18**, this time employing compound **12** and TsCl. The compound **20** was purified by crystallization from ether and hexane with an yield of 93%; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.55 (d, 3H), 1.53-1.62 (m, 4H), 2.43 (s, 3H), 3.82 (q, 1H), 3.92 (s, 3H), 3.94 (m, 2H), 4.02 (m, 2H), 7.11-7.15 (m, 2H), 7.30 (d, 2H), 7.38 (d, 1H), 7.64 (d, 1H), 7.70 (d, 2H), 7.75 (d, 2H); MS (ESI) *m/z* 457.5 (M+1).

#### Example 4

**Compound 13** (Scheme 2). Compound **13** was prepared as described above for the preparation of compound **10**, this time employing naproxen (**1**) and 1,5-pentanediol (**5**). After reaction, the reaction solution was washed with water and the reaction solvent was then evaporated under high vacuum to give a quantitative yield of the compound **13**. The compound was used to make compound **21** without further purification;  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.28 (m, 2H), 1.46 (m, 2H), 1.55 (d, 3H), 1.59 (m, 2H), 3.51 (t, 2H), 3.85 (q, 1H), 3.91 (s, 3H), 4.09 (t, 2H), 7.11-7.15 (m, 2H), 7.40 (q, 1H), 7.66-7.70 (m, 3H); MS (ESI)  $m/z$  317.5 (M+1).

**Compound 21** (Scheme 2). Compound **21** was prepared as described above for the preparation of compound **18**, this time employing compound **13** and TsCl. Compound **21** was purified by crystallization from ether and hexane with a 95% yield;  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.24 (m, 2H), 1.48-1.58 (m, 4H), 1.59 (d, 3H), 2.43 (s, 3H), 3.84 (q, 1H), 3.89 (t, 2H), 3.91 (s, 3H), 4.01 (t, 2H), 7.11-7.15 (m, 2H), 7.32 (q, 2H), 7.39 (q, 1H), 7.65 (d, 1H), 7.70 (m, 2H), 7.75 (d, 2H); MS (ESI)  $m/z$  471.7 (M+1).

#### Example 5

**Compound 14** (Scheme 2). Compound **14** was prepared as described above for the preparation of compound **10**, this time employing naproxen (**1**) and 1,6-hexanediol (**6**). After reaction, the reaction solution was washed with water and the reaction solvent was then evaporated to give compound **14** as a solid. The compound was used to make compound **22** without further purification;  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.24 (m, 4H), 1.43 (m, 2H), 1.56 (d, 3H), 1.54 (m, 2H), 3.51 (t, 2H), 3.85 (q, 1H), 4.01 (m, 2H), 7.10-7.15 (m, 2H), 7.40 (q, 1H), 7.66-7.70 (m, 3H); MS (ESI)  $m/z$  331.7 (M+1).

**Compound 22** (Scheme 2). Compound **22** was prepared as described above for the preparation of compound **18**, this time employing compound **14** and TsCl. Compound **22** was purified by column chromatography on a silica gel column using dichloromethane as an eluent to give compound **22** as a pale yellow oil; The  $^1\text{H}$  NMR

(CDCl<sub>3</sub>) δ 1.12–1.22 (m, 4H), 1.46–1.52 (m, 4H), 1.57 (d, 3H), 2.43 (s, 3H), 3.84 (q, 1H), 3.92 (s, 3H), 3.93 (m, 2H), 4.03 (m, 2H), 7.11–7.77 (m, 10H); MS (ESI) *m/z* 485.6 (M+1).

### Example 6

**Compound 15** (Scheme 2). Compound **15** was prepared as described above for the preparation of compound **10**, this time employing naproxen (**1**) and di(ethylene glycol) (**7**). After reaction, the reaction solution was washed with water and the reaction solvent was then evaporated to give compound **15**. The compound was used to make compound **23** without further purification; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.58 (d, 3H), 1.93 (br, 1H, D<sub>2</sub>O ex), 3.43 (t, 2H), 3.59 (t, 2H), 3.62 (t, 2H), 3.89 (q, 1H), 3.90 (s, 3H), 4.25 (m, 2H), 7.11–7.15 (m, 2H), 7.40–7.42 (m, 1H), 7.70 (t, 3H); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 18.7, 45.6, 55.5, 61.8, 64.0, 69.2, 72.4, 76.9, 77.2, 77.5, 105.7, 119.2, 126.2, 126.4, 127.3, 129.0, 133.9, 135.7, 157.9, 174.8; MS(ESI) *m/z* 319.3 (M+1).

**Compound 23** (Scheme 2). Compound **23** was prepared as described above for the preparation of compound **18**, this time employing compound **15** and TsCl.

Compound **23** was purified by column chromatography on a silica gel column using dichloromethane as an eluent to give the compound as a pale yellow oil with a 93% yield. The <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.58 (d, 3H), 2.41 (s, 3H), 3.43 (m, 2H), 3.48 (m, 2H), 3.84 (q, 1H), 3.86 (s, 3H), 3.94 (t, 2H), 4.10 (m, 2H), 7.10–7.13 (m, 2H), 7.29 (d, 2H), 7.39 (d, 1H), 7.65–7.75 (m, 5H); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 18.6, 21.8, 45.5, 55.5, 63.9, 68.7, 69.27, 69.27, 105.8, 119.2, 126.2, 126.4, 127.4, 128.1, 129.0, 129.4, 129.9, 133.9, 145.0, 157.9, 174.7; MS (ESI) *m/z* 473.4 (M+1).

### Example 7

**Compound 16** (Scheme 2). Compound **16** was prepared as described above for the preparation of compound **10**, this time employing naproxen (**1**) and 1,3-pentanediol (**8**). After reaction, the reaction solution was washed with water and the reaction solvent was then evaporated to give compound **15** with a 32% yield. The compound was used to make compound **24** without further purification; <sup>1</sup>H NMR, <sup>13</sup>C



NMR and MS are consistent with the structure of compound **16**.

**Compound 24** (Scheme 2). Compound **24** was prepared as described above for the preparation of compound **18**, this time employing compound **16** and TsCl. The compound **24** was purified by column chromatography on a silica gel column using dichloromethane as an eluent to give the compound as a pale yellow oil with a 82% yield. The  $^1\text{H}$  NMR,  $^{13}\text{C}$  NMR and MS are consistent with the structure of compound **24**.



### Example 8

**Compound 17** (Scheme 2). Compound **17** was prepared as described above for the preparation of compound **10**, this time employing naproxen (**1**) and 1,4-cyclohexanediol (**8**). After reaction, the reaction solution was washed with water and the reaction solvent was then evaporated to give compound **17**. Compound **17** was used to make compound **25** without further purification;  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.30-1.45 (m, 6H), 1.56 (d, 3H), 1.80-1.98 (m, 4H), 3.66 (m, 1H), 3.82 (q, 1H), 3.91 (s, 3H), 4.75 (m, 1H), 7.11 (m, 2H), 7.39 (d, 1H), 7.65-7.70 (m, 3H);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ) 18.7, 28.2, 28.5, 32.1, 32.2, 45.9, 55.5, 68.9, 72.0, 76.9, 77.2, 77.5, 105.8, 119.1, 126.0, 126.4, 127.2, 129.1, 129.5, 133.8, 136.1, 157.8, 174.4; MS (ESI)  $m/z$  351.4 (M + Na).


**Compound 25** (Scheme 2). Compound **25** was prepared as described above for the preparation of compound **18**, this time employing compound **17** and TsCl. Compound **25** was purified by column chromatography on a silica gel column using dichloromethane as an eluent to give the compound as a pale yellow oil with a 93% yield;  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.50-1.84 (m, 11H), 2.43 (s, 3H), 3.80 (q, 1H), 3.92 (s, 3H), 4.51 (m, 1H), 4.78 (m, 1H), 7.10-7.15 (m 2H), 7.26-7.39 (m, 3H), 7.61-7.75 (m, 5H); MS (ESI)  $m/z$  483.5 (M+H).

The syntheses described in Examples 9-14 are outlined in Scheme 3.


**Scheme 3**




Ketoprofen




Ibuprofen




Carprofen



Flurbiprofen



Diclofenac



Indomethacin

### Example 9

**Compound 32** (Scheme 3). Compound **32** was prepared as described above for the preparation of compound **10**, this time employing ketoprofen (**26**) and 1,3-propanediol (**3**). Compound **32** was purified by column chromatography on a silica gel column using 200:1 CH<sub>2</sub>Cl<sub>2</sub>/MeOH as an eluent to give compound **32** with a 50% yield. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.55 (d, 3H), 1.82 (m 3H, 1H, D<sub>2</sub>O ex), 3.58 (m, 2H), 3.82(m, 1H), 4.25 (m 2H), 7.44-7.82 (m, 9H); MS (ESI) *m/z* 313.5 (M+H).

**Compound 38** (Scheme 3). Compound **38** was prepared as described above for the preparation of compound **18**, this time employing compound **32** and TsCl. Compound **38** was purified by column chromatography on a silica gel column using CH<sub>2</sub>Cl<sub>2</sub> as an eluent to give the compound **38** as a colorless oil with a 81% yield; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.49 (d, 3H), 1.94 (m, 2H), 2.43 (s, 3H), 3.72 (q, 1H), 4.01 (t, 2H), 4.12 (m, 2H), 7.31-7.78 (m, 13H); MS (ESI) *m/z* 467.3 (M+H).

### Example 10

**Compound 33** (Scheme 3). Compound **33** was prepared as described above for the preparation of compound **10**, this time employing flurbiprofen (**27**) and 1,3-propanediol (**3**). After reaction, the reaction solution was washed in water and the reaction solvent was then evaporated to give the compound **33** with a quantitative yield. The compound **33** was used to make compound **39** without further purification; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.54 (d, 3H), 1.79 (t, 1H, D<sub>2</sub>O ex), 1.85 (m, 2H), 3.63 (m, 2H), 3.76 (q, 1H), 4.27 (t, 2H), 7.11-7.16(m, 2H), 7.35-7.46 (m, 4H), 7.54 (d, 2H); MS (ESI) *m/z* 325.4 (M+Na).

**Compound 39** (Scheme 3). Compound **39** was prepared as described above for the preparation of compound **18**, this time employing compound **33** and TsCl. Compound **39** was purified by crystallization from ether/hexane system with a 79% yield; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.50 (d, 3H), 1.96 (m, 2H), 2.42 (s, 3H), 3.68 (q, 1H), 4.03 (t, 2H), 4.15 (t, 2H), 7.05-7.11 (m, 2H), 7.25-7.54 (m, 8H), 7.76 (d, 2H); <sup>13</sup>C NMR

(CDCl<sub>3</sub>)  $\delta$  18.4, 21.8, 28.4, 45.0, 50.8, 66.9, 115.2, 115.5, 123.68, 123.7, 127.9, 128.0, 129.2, 130.1, 131.0, 133.1, 135.6, 141.75, 141.8, 145.1, 158.9, 160.9, 173.9; MS (ESI)  $m/z$  479.4 (M+Na).

5

### Example 11

**Compound 34** (Scheme 3). Compound **34** was prepared as described above for the preparation of compound **10**, this time employing ibuprofen (**28**) and 1,3-propanediol (**3**). After reaction, the reaction solution was washed in water and the reaction solvent was then evaporated to give compound **34** with a quantitative yield.

10 The compound **34** was used to make compound **40** without further purification; <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  0.89 (d, 6H), 1.49 (d, 3H), 1.79 (t, 2H), 1.78-1.85 (m, 1H), 1.95 (t, 1H, D<sub>2</sub>O ex), 2.45 (d, 2H), 3.53 (m, 2H), 3.71 (q, 1H), 4.22 (m, 2H), 7.09 (d, 2H), 7.26 (d, 2H).

15 **Compound 40** (Scheme 3). Compound **40** was prepared as described above for the preparation of compound **18**, this time employing compound **34** and TsCl. Compound **40** was purified by crystallization from ether/hexane system to give a white solid with a 96% yield; <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  0.89 (d, 6H), 1.44 (d, 3H), 1.81-1.92 (m, 3H), 2.44 (s, 3H), 3.61 (q, 1H), 3.99 (t, 2H), 4.09 (t, 2H), 7.08 (d, 2H), 7.14  
20 (d, 2H), 7.34 (d, 2H), 7.78 (d, 2H); <sup>13</sup>C NMR (CDCl<sub>3</sub>)  $\delta$  18.46, 21.80, 22.54, 28.39, 30.32, 45.16, 60.39, 66.92, 127.23, 128.04, 129.50, 130.03, 133.12, 137.68, 140.76, 145.00, 174.54; MS (ESI)  $m/z$  441.5 (M + Na).

### Example 12

25 **Compound 35** (Scheme 3). Compound **35** was prepared as described above for the preparation of compound **10**, this time employing diclofenac (**29**) and 1,3-propanediol (**3**). After reaction, compound **35** was purified by column chromatography on a silica gel column using 200:1 CH<sub>2</sub>Cl<sub>2</sub>/MeOH as an eluent to give the compound **35** as a white solid with a 56% yield. <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  1.89 (s,  
30 3H, 1H D<sub>2</sub>O ex), 3.66 (t, 2H), 3.83 (s, 3H), 4.31 (t, 2H), 6.55 (d, 1H), 6.87 (br, 1H), 6.94-7.00 (m, 2H), 7.11-7.14 (m, 1H), 7.22-7.26 (m, 1H), 7.34 (d, 2H); MS (ESI)  $m/z$

376.3 (M+Na).

**Compound 41** (Scheme 3). Compound **41** was prepared as described above for the preparation of compound **18**, this time employing compound **35** and TsCl.

- 5 Compound **41** was purified by column chromatography on a silica gel column using  $\text{CH}_2\text{Cl}_2$  as an eluent to give the compound **41** as a pale yellow oil and the yield was 89%;  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  2.02 (m, 2H), 2.43 (s, 3H), 3.73 (s, 2H), 4.09 (t, 2H), 4.17 (t, 2H), 6.53 (d, 1H), 6.99 (s, 1H), 6.93-7.00 (m, 2H), 7.12 (t, 1H), 7.18 (d, 1H), 7.23 (d, 1H), 7.31-7.35 (m, 3H), 7.78 (d, 2H); MS (ESI)  $m/z$  508.3 (M).

10

### Example 13

**Compound 36** (Scheme 3). Compound **36** was prepared as described above for the preparation of compound **10**, this time employing carprofen (**30**) and 1,3-propanediol (**3**). After reaction, compound **36** was purified by column

- 15 chromatography on a silica gel column using 200:1  $\text{CH}_2\text{Cl}_2/\text{MeOH}$  as an eluent to give the compound **36** as a colorless oil with a 54% yield.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.59 (d, 3H), 1.74 (br, 1H,  $\text{D}_2\text{O}$  ex), 1.80 (m, 2H), 3.53-3.56 (m, 2H), 3.88 (q, 1H), 4.22-4.28 (m, 2H), 7.17 (d, 1H), 7.29-7.35 (m, 3H), 7.94-7.98 (m, 2H), 8.14 (br, 1H);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  18.99, 31.84, 46.17, 59.42, 62.10, 109.70, 111.79, 119.79, 120.21, 20 120.87, 121.92, 124.49, 125.22, 126.09, 138.24, 139.37, 140.55, 175.39; MS (ESI)  $m/z$  332.2 (M+H).

**Compound 42** (Scheme 3). Compound **42** was prepared as described above for the preparation of compound **18**, this time employing compound **36** and TsCl.


- 25 Compound **42** was purified by column chromatography on a silica gel column using  $\text{CH}_2\text{Cl}_2$  as an eluent to give the compound **42** as a sticky oil and the yield was 90%; The  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.55 (d, 3H), 1.91 (m, 2H), 2.39 (s, 3H), 3.83 (q, 1H), 3.97 (t, 2H), 4.09-4.18 (m, 2H), 7.10 (d, 1H), 7.21(d, 2H), 7.32 (s, 2H), 7.38 (s, 1H) 7.65 (d, 2H), 7.91 (d, 1H), 7.98 (s, 1H), 8.54 (s, 1H);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  18.83, 21.77, 28.32, 30 46.08, 60.59, 57.04, 109.97, 111.97, 119.58, 120.06, 120.69, 121.77, 124.38, 125.00, 125.99, 127.95, 129.22, 130.06, 132.90, 138.38, 139.19, 140.69, 145.15, 174.59; MS

10

## 15

20

### Scheme 4





### Example 17


**Compound 50** (Scheme 5). To a solution of naproxen (**1**) (1.15g, 5 mmol), compound **48** (0.62g, 5 mmol) and dimethylamino pyridine (DMAP) (0.12g, 1 mmol) was added dicyclohexyldicarbodiimide (DCC) (1.03g, 5 mmol) at 0° C. The resulting solution was stirred at 0° C for 1.5 h. After reaction, the solid was filtered off and the solvent was evaporated. The residue was washed with ether to give 1.4g (83%) of compound **50** as a white solid; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.59 (d, 3H), 2.38 (s, 3H), 3.17 (m, 2H), 3.87 (q, 1H), 3.92 (s, 3H), 4.43 (m, 1H), 4.59 (m, 1H), 7.10 (d, 1H), 7.15 (m, 1H), 7.33 (m, 1H), 7.67 (d, 1H), 7.70 (m, 2H); MS (ES) *m/e* 358.2 (M+Na).

### Example 18

**Compound 51** (Scheme 5). Compound **51** was prepared as described above for the preparation of compound **50**, this time employing compound **1** (1.15g, 5mmol) and **49** (1.16g, 5 mmol). The compound was purified by column chromatography on a silica gel column using 1:1 hexanes/ethyl acetate as eluent to give 0.91g of compound **51** as a pale yellow oil; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.45 (d, 3H), 3.48 (m, 2H), 3.59 (q, 1H), 3.92 (s, 3H), 4.47 (m, 2H), 7.10 (d, 1H), 7.18 (m, 2H), 7.45 (s, 1H), 7.49 (t, 1H), 7.65 (t, 2H), 8.06 (q, 1H), 8.28 (q, 1H), 8.68 (s, 1H); <sup>13</sup>C NMR (CDCl<sub>3</sub>) 18.8, 45.2, 55.4, 55.5, 57.9, 105.8, 123.6, 125.9, 127.5, 128.4, 129.0, 129.3, 130.8, 133.7, 133.9, 134.9, 141.5, 148.4, 158.0, 174.0.

The syntheses described in Examples 19-21 are outlined in Scheme 6.

### Scheme 6





**Example 19**

**Compound 55** (Scheme 6). A mixture of compound **19** (2.2g, 5 mmol), compound **52** (0.57g, 6mmol) and  $K_2CO_3$  (3.45g, 25 mmol) in 50 ml of dimethyl formamide (DMF) was stirred for a week. The reaction solution was poured into 100  
 5 ml of water and extracted with  $CH_2Cl_2$ . The organic phase was washed with water (50 x 5) and dried ( $Na_2SO_4$ ). The solvent was evaporated and the residue was purified by column chromatography on a silica gel column using 3:1 hexane/ ethylacetate as an eluent to give 0.3g (16%) of compound **55** as a pale yellow oil;  $^1H$  NMR ( $CDCl_3$ )  $\delta$  1.60 (d, 3H), 2.38 (s, 3H), 3.17 (m, 2H), 3.87 (q, 1H), 3.92 (s, 3H), 4.45 (m, 1H), 4.59  
 10 (m, 1H), 7.10 (s, 1H), 7.14–7.16 (q, 1H), 7.32–7.35 (q, 1H), 7.62 (s, 1H), 7.67–7.71 (m, 2H); MS (ESI)  $m/z$  358.2 (M + Na).

**Example 20**

**Compound 56** (Scheme 6). Compound **56** was prepared as described above  
 15 for the preparation of compound **55**, this time employing compound **19** and compound **53**. The compound was purified by column chromatography on a silica gel column using  $CH_2Cl_2$  as an eluent to give compound **56** as a pale yellow oil (33%).  $^1H$ NMR ( $CDCl_3$ )  $\delta$  1.54 (d, 3H), 1.72 (m, 2H), 2.83 (m, 2H), 3.80 (q, 1H), 3.92 (s, 3H), 4.10 (t, 2H) 7.07–8.10 (m, 10H); MS (ESI)  $m/z$  442.3 (M + H).

20


**Example 21**

**Compound 57** (Scheme 6). Compound **57** was prepared as described above  
 for the preparation of compound **55**, this time employing compound **19** and compound  
 54. The compound was purified by column chromatography on a silica gel column  
 25 using  $CH_2Cl_2$  as an eluent to give compound **57** as a pale yellow oil (11%). The  $^1H$ NMR ( $CDCl_3$ )  $\delta$  1.55 (d, 3H), 1.80 (m, 2H), 3.03 (m 2H), 3.86 (m, 1H), 4.13 (m, 2H), 7.07–7.93 (m, 10H); MS (ESI)  $m/z$  473.4 (M + H).

The syntheses described in Examples 22 and 23 are outlined in Scheme 7.

### Scheme 7

5



15

### Example 22

**Compound 60** (Scheme 7). Compound 60 is prepared as described above for the preparation of compound 50, this time employing naproxen 1 and compound 58. After reaction the compound is purified by column chromatography on a silica gel column to give the compound 60 in a yield from 75 –95%.

20


### Example 23

**Compound 61** (Scheme 7). Compound 61 is prepared as described above for the preparation of compound 50, this time employing naproxen (1) and compound 59. After reaction, the compound is purified by column chromatography on a silica gel column to give compound 61 in a yield from 75 –95%.

25

The syntheses described in Examples 24 and 25 are outlined in Scheme 8.

**Scheme 8**



**Example 24**

**Compound 63** (Scheme 8). Compound **63** is prepared as described above for the preparation of compound **50**, this time employing naproxen (**1**) and compound **62**. After reaction, the compound is purified by column chromatography on a silica gel column to give compound **63** in a yield of 75–95%.

**Compound 66** (Scheme 8). Compound **66** is prepared as described above for the preparation of compound **18**, this time employing compound **63** and compound **64**.


**Example 25**

**Compound 67** (Scheme 8). Compound **67** is prepared as described above for the preparation of compound **18**, this time employing compound **63** and compound **65**.

The syntheses described in Examples 26 and 27 are outlined in Scheme 9.

### Scheme 9

5



15

### Example 26


20      **Compound 70** (Scheme 9). Compound 70 is prepared as described above for the preparation of compound 60, this time employing compound 1 and compound 68.

### Example 27

**Compound 71** (Scheme 9). Compound 71 is prepared as described above for the preparation of compound 60, this time employing compound 1 and compound 69.

The synthesis described in Example 28 is outlined in Scheme 10.

### Scheme 10




### Example 28

**Compound 73** (Scheme 10). Compound 73 is prepared as described above for the preparation of compound 60, this time employing compound 1 and compound 72.

The synthesis described in Example 29 is outlined in Scheme 11.

### Scheme 11



### Example 29

**Compound 75** (Scheme 11). Compound 75 is prepared as described above for the preparation of compound 60, this time employing compound 1 and compound 74.

**Example 30**

5        Reduced numbers of intestinal ulcers in rat acute and subacute enteropathy  
      models by the invention modified NSAID (compound 19), a prodrug of naproxen

NSAIDs are important drugs used to treat acute and chronic inflammation as well as pain and fever. The major limitation to NSAID use is the occurrence of gastrointestinal ulcers and erosions. These side effects are produced by a combination of local and systemic effects. Attempts have been made to circumvent the local side effects of NSAIDs by making them as prodrugs, which will bypass the stomach, but so far this has not been clearly successful. It is demonstrated here that the invention modified NSAIDs substantially reduce GI toxicity, while exhibiting dose equivalent efficacy in anti-inflammation activity in both acute and chronic inflammation animal models.

Sprague-Dawley rats (male, 150 - 200 g), were orally dosed once daily for either 3 days (acute model) or 14 days (subacute model). Twenty-four hours after the last dose, the rats were injected i.v. with Evans Blue (5 ml/kg, 10 mg/ml) to stain the ulcers. Ten to twenty minutes later the animals were sacrificed by CO<sub>2</sub> inhalation and the intestines removed, opened lengthwise and the contents removed. The long dimensions of all ulcers were measured using a ruler and summed to give a total ulcer score.

In the acute model (Figure 1), ulceration after dosing with an invention modified NSAID (compound 19) was 15% of that seen with an equimolar dose of naproxen. PEG had no ulcerogenic effect. In the subacute model (Figure 2), ulceration was less than 5% of that seen with a corresponding dose of naproxen at all three doses used. Again, PEG had no effect. These results suggest that invention modified NSAIDs are much less ulcerogenic than naproxen.

**Example 31**

Reduction of chronic hindlimb inflammation in the rat adjuvant arthritis model by the invention modified NSAID (compound 19), a prodrug of naproxen

NSAIDs are useful in the treatment of both chronic and acute inflammatory conditions. Efficacy in chronic inflammation can be estimated using the rat adjuvant arthritis model. In this model Lewis male rats (175-250 g) are injected intradermally in the footpad with M. tuberculosis powder suspended in mineral oil at 5 mg/ml. Progressive swelling of the uninjected paw and ankle joint between days 5 and 15 is measured by plethysmometry.

Rats were dosed daily by oral gavage with 5 ml/kg of naproxen at 3 to 30 mg/kg in phosphate buffered saline (PBS) and with equimolar doses of an invention modified NSAID at 1 ml/kg in PEG 300. The results (Figure 3) show that the invention modified NSAID resulted in antiinflammatory effects comparable to those of naproxen in this model.

**Example 32**

Reduction of acute hindlimb inflammation in the rat carrageenan-induced hindlimb edema model by the invention modified NSAID (compound 19), a prodrug of naproxen

Efficacy of NSAIDs in acute inflammation can be estimated by using intraplantar injection of carrageenan in the rat. Sprague-Dawley rats (200-250 g male) are injected intradermally in the footpad with 50  $\mu$ l of a 1% carrageenan solution in PBS. Swelling of the injected paw is measured 3 & 4 hours later, using a plethysmometer.

Pretreatment with oral naproxen one hour before the carrageenan injection at 10 mg/kg resulted in an approximately 50% reduction in swelling at both time points (Table 1). An equimolar dose of an invention modified NSAID reduced inflammation to the same degree at both time points. These results suggest that invention modified NSAIDs are comparable in effect to naproxen at 10 mg/kg.

**Table 1.** Effects of naproxen and the invention modified NSAID (compound 19) on paw volume increase in carrageenan-induced inflammation in rats.

Treatment	4 Hours	5 Hours
Vehicle	$0.73 \pm 0.10$	$0.85 \pm 0.10$
Naproxen (1 mg/kg)	$0.63 \pm 0.07$	$0.75 \pm 0.08$
Naproxen (10 mg/kg)	$0.32 \pm 0.05^*$	$0.39 \pm 0.07^*$
Compound 19 (1.75 mg/kg)	$0.78 \pm 0.04$	$0.93 \pm 0.04$
Compound 19 (17.5 mg/kg)	$0.34 \pm 0.06^*$	$0.40 \pm 0.06^*$

5 \*P < 0.05 vs Vehicle by unpaired t-test.

Invention modified NSAIDs are seen to have antiinflammatory activity similar to naproxen in the chronic adjuvant arthritis and acute carrageenan hindlimb edema rat models. The tendency to cause intestinal ulcers is reduced substantially invention modified NSAID. Thus, invention modified NSAIDs provide an effective prodrug form of naproxen with reduced intestinal side effects.

### Example 33

#### Plasma pharmacokinetics of naproxen and the invention modified NSAID after oral administration in rats

The invention compound (compound 19) is a naproxen prodrug, which is a conjugate of naproxen and tosylate. Oral administration of the invention compound resulted in the release of free naproxen. The pharmacokinetics of naproxen release from the invention modified NSAID and its parent drug, naproxen, was evaluated in rats after oral administration.

The carotid artery of Sprague-Dawley rat (250-350 g, male) was catheterized at least one day before drug administration and flushed with 30% polyvinyl pyrrolidone (PVP) (400 U/mL of heparin) to maintain patency. At predetermined time points (see Table 2), blood samples (250  $\mu$ L) were collected by unhooking the flushing syringe and letting the blood flow out of the catheter and into the centrifuge



tubes. After centrifugation (13,000 rpm, 10 min, 4°C), the plasma samples were collected and analyzed in the same day.

**Table 2:** Rat group assignment and doses

Test Article	Group #	Rat #	Dose* (mg/kg)	Sample Time
Naproxen	1	1, 2, 3, & 4	Oral (2 mg/kg)	5 min, 0.5, 1, 4, 7, 10, 13, 16, 19, 22, & 24 hrs
Invention Compound 19	2	5, 6, 7, & 8	Oral (2 mg/kg)	15 min, 0.5, 1, 3, 5, 6, 7, 8, 22, 23, & 24 hrs

\*Indicates amount of naproxen in dose.

Aliquot of plasma sample (100  $\mu$ L) was mixed with 200  $\mu$ L of acetonitrile. After vortexing and centrifugation (13,000 rpm, 10 min, 4°C), 200  $\mu$ L of supernatant was removed and added to 300  $\mu$ L of a 58:42 mixture of 50 mM phosphate buffer (pH 5.0) and acetonitrile. Following vortexing and centrifugation, 25  $\mu$ L of supernatant was removed and analyzed by HPLC with a UV detection system.

The average plasma concentration at each time point was calculated and utilized in a pharmacokinetic analysis. Noncompartmental pharmacokinetic analysis was carried out using WinNolin (Pharsight, Mountainview, California) to calculate the maximum concentration ( $C_{max}$ ), time to maximum concentration ( $T_{max}$ ), area under the curve from zero to the last time point ( $AUC_{last}$ ), the area under the curve from zero to infinite time ( $AUC_{inf}$ ), and the terminal phase half life ( $Beta-t_{1/2}$ ).

The  $AUC_{all}$ ,  $AUC_{INF}$ , and  $t_{1/2}$  of naproxen from naproxen and a modified form of naproxen according to the invention were found to be similar (Table 3). On the other hand, for the invention modified form of neproxen, the  $C_{max}$  was lower and the  $T_{max}$  longer, compared to naproxen (see Table 3).

**Table 3 - Non-Compartmental Pharmacokinetic Analysis of naproxen and the invention modified form of naproxen according to the (compound 19) after oral administration in rats**

5

Drug	Dose*	C <sub>max</sub>	T <sub>max</sub>	AUC <sub>all</sub>	AUC <sub>INF</sub>	t <sub>1/2</sub>	N
	(mg/kg)	(µg/mL)	(hrs)	(µg*hr/mL)		(hrs)	
Naproxen	2	7.77±4.13	0.5±0.5	50±6	55±7	6.2±0.4	4
Invention modified naproxen	2	3.87±1.05	6.8±1.5	49±10	56±14	6.8±2.7	4

\*Indicates amount of naproxen in dose.

- 10 Following oral naproxen administration, the naproxen plasma levels were at the highest at the first time-point (5 minutes) then declined in a bi-exponential manner. In contrast, after oral administration of a modified form of naproxen according to the invention, the maximum naproxen levels were observed at a much later time (T<sub>max</sub> of 6.8±1.5 hrs). The similar AUC<sub>all</sub>, AUC<sub>INF</sub>, and T<sub>1/2</sub> values but lower
- 15 C<sub>max</sub> and longer T<sub>max</sub> values supports the conclusions drawn from the results obtained from pharmacological studies, i.e. that a modified form of naproxen according to the invention conjugate has equivalent pharmacological efficacy and greatly improved gastrointestinal safety profile compared to naproxen.

- 20 While the invention has been described in detail with reference to certain preferred embodiments thereof, it will be understood that modifications and variations are within the spirit and scope of that which is described and claimed.

That which is claimed is:

1. A compound having the structure:

5 X-L-Z

wherein:

X = a non-steroidal anti-inflammatory drug (NSAID),

L = an optional linker/spacer,

10 Z = a sulfur-containing functional group containing an optionally substituted hydrocarbyl moiety.

2. A compound according to claim 1 wherein said NSAID is acetaminophen, aspirin, ibuprofen, choline magnesium salicylate, choline salicylate,  
15 diclofenac, diflunisal, etodolac, fenpropfen calcium, flurbiprofen, indomethacin, ketoprofen, carprofen, indoprofen, ketorolac tromethamine, magnesium salicylate, meclofenamate sodium, mefenamic acid, oxaprozin, piroxicam, sodium salicylate, sulindac, tolmetin, meloxicam, nabumetone, naproxen, lornoxicam, nimesulide, indoprofen, remifenzone, salsalate, tiaprofenic acid, or flosulide.

- 20 3. A compound according to claim 2 wherein said NSAID is naproxen, aspirin, ibuprofen, flurbiprofen, indomethacin, ketoprofen, or carprofen.

- 25 4. A compound according to claim 1 wherein the sulfur-containing functional group is sulfonate, reverse sulfonate, sulfonamide, reverse sulfonamide, sulfone, sulfinate, or reverse sulfinate.

5. A compound according to claim 4 wherein the sulfur-containing functional group is sulfonate or reverse sulfonate.

6. A compound according to claim 5 wherein the sulfur-containing functional group is an optionally substituted aromatic sulfonate.

5 7. A compound according to claim 6 wherein said aromatic sulfonate is tosylate or brosylate.

8. A compound according to claim 5 wherein the sulfur-containing functional group is an optionally substituted C<sub>1</sub> to C<sub>10</sub> alkyl sulfonate.

10 9. A compound according to claim 8 wherein the alkyl sulfonate is mesylate or triflate.

15 10. A compound according to claim 4 wherein the sulfur-containing functional group is a sulfone.

11. A compound according to claim 10 wherein the sulfur-containing functional group is an optionally substituted C<sub>1</sub> to C<sub>10</sub> alkyl sulfone.

20 12. A compound according to claim 11 wherein said sulfone is methyl sulfone, ethyl sulfone.

13. A compound according to claim 10 wherein the sulfur-containing functional group is an optionally substituted aromatic sulfone.

25 14. A compound according to claim 13 wherein the sulfur-containing functional group is a *p*-substituted aromatic sulfone.

30 15. A compound according to claim 4 wherein the sulfur-containing functional group is a sulfonamide or reverse sulfonamide.

16. A compound according to claim 15 wherein the sulfur-containing functional group is an optionally substituted C<sub>1</sub> to C<sub>10</sub> alkyl sulfonamide.

17. A compound according to claim 16 wherein the sulfur-containing functional group is methyl sulfonamide.

18. A compound according to claim 15 wherein the sulfur-containing functional group is an optionally substituted aromatic sulfonamide.

19. A compound according to claim 18 wherein the sulfur-containing functional group is toluene sulfonamide.

20. A compound according to claim 4 wherein the sulfur-containing functional group is a sulfinate or reverse sulfinate.

21. A compound according to claim 1 wherein L, when present, has the structure:



wherein:

R is optional, and when present is alkylene, substituted alkylene, cycloalkylene, substituted cycloalkylene, heterocyclic, substituted heterocyclic, oxyalkylene, substituted oxyalkylene, alkenylene, substituted alkenylene, arylene, substituted arylene, alkarylene, substituted alkarylene, aralkylene or substituted aralkylene, and

W is ester, reverse ester, thioester, reverse thioester, amide, reverse amide, phosphate, phosphonate, imine or enamine.

22. A formulation comprising a compound according to claim 1 in a pharmaceutically acceptable carrier therefor.

23. A formulation according to claim 22 wherein said pharmaceutically acceptable carrier is a solid, solution, emulsion, dispersion, micelle or liposome.

5 24. A formulation according to claim 22 wherein said pharmaceutically acceptable carrier further comprises an enteric coating.

25. In a method for the administration of a non-steroidal anti-inflammatory drug (NSAID) to a subject for the treatment of a pathological condition, the  
10 improvement comprising directly or indirectly covalently attaching said NSAID to a sulfur-containing functional group containing an optionally substituted hydrocarbyl moiety prior to administration thereof to said subject.

26. The method of claim 25 wherein said pathological condition is septic  
15 shock, hemorrhagic shock, anaphylactic shock, toxic shock syndrome, ischemia, cerebral ischemia, administration of cytokines, overexpression of cytokines, ulcers, inflammatory bowel disease, diabetes, arthritis, asthma, Alzheimer's disease, Parkinson's disease, multiple sclerosis, cirrhosis, allograft rejection, encephalomyelitis, meningitis, pancreatitis, peritonitis, vasculitis, lymphocytic choriomeningitis, glomerulonephritis,  
20 uveitis, ileitis, inflammation, burn, infection, hemodialysis, chronic fatigue syndrome, stroke, cancers, cardiopulmonary bypass, ischemic/reperfusion injury, gastritis, adult respiratory distress syndrome, cachexia, myocarditis, autoimmune disorders, eczema, psoriasis, heart failure, heart disease, atherosclerosis, dermatitis, urticaria, systemic lupus erythematosus, AIDS, AIDS dementia, chronic neurodegenerative disease,  
25 chronic pain, priapism, cystic fibrosis, amyotrophic lateral sclerosis, schizophrenia, depression, premenstrual syndrome, anxiety, addiction, migraine, Huntington's disease, epilepsy, neurodegenerative disorders, gastrointestinal motility disorders, obesity, hyperphagia, solid tumors, malaria, hematologic cancers, myelofibrosis, lung injury, graft-versus-host disease, head injury, CNS trauma, hepatitis, renal failure, liver disease,  
30 drug-induced lung injury, myasthenia gravis (MG), ophthalmic diseases, post-angioplasty, restenosis, angina, or coronary artery disease.

27. In the treatment of a subject suffering from a pathological condition by administration thereto of a non-steroidal anti-inflammatory drug (NSAID), the improvement comprising covalently attaching said NSAID to a sulfur-containing functional group containing an optionally substituted hydrocarbyl moiety prior to administration thereof to said subject.

28. A method for the treatment of a subject afflicted with a pathological condition, said method comprising administering to said subject an effective amount of a non-steroidal anti-inflammatory drug (NSAID),  
wherein said NSAID is effective for treatment of said condition, and  
wherein said NSAID has been modified by the direct or indirect covalent attachment thereto of a sulfur-containing functional group containing an optionally substituted hydrocarbyl moiety.

29. A method for the preparation of a protected form of a non-steroidal anti-inflammatory drug (NSAID), said method comprising directly or indirectly covalently attaching a sulfur-containing functional group containing an optionally substituted hydrocarbyl moiety to said NSAID.

30. A method according to claim 29 wherein said NSAID is acetaminophen, aspirin, ibuprofen, choline magnesium salicylate, choline salicylate, diclofenac, diflunisal, etodolac, fenpropfen calcium, flurbiprofen, indomethacin, ketoprofen, carprofen, indoprofen, ketorolac tromethamine, magnesium salicylate, meclofenamate sodium, mefenamic acid, oxaprozin, piroxicam, sodium salicylate, sulindac, tolmetin, meloxicam, nabumetone, naproxen, lornoxicam, nimesulide, indoprofen, remifenzone, salsalate, tiaprofenic acid, or flosulide.

31. A method for reducing the side effects induced by administration of a non-steroidal anti-inflammatory drug (NSAID) to a subject, said method comprising directly or indirectly covalently attaching a sulfur-containing functional group  
5 containing an optionally substituted hydrocarbyl moiety to said NSAID prior to administration to said subject.

32. A method for enhancing the effectiveness of a non-steroidal anti-inflammatory drug (NSAID), said method comprising directly or indirectly covalently  
10 attaching a sulfur-containing functional group containing an optionally substituted hydrocarbyl moiety to said NSAID.

33. A method for the prevention or treatment of an inflammatory or infectious disease in a subject in need thereof, said method comprising administering to  
15 said subject an amount of the compound of claim 1 effective to alleviate said condition.



ABSTRACT

In accordance with the present invention, there are provided normal modified forms of nonsteroidal anti-inflamamatory drugs. Modified NSAIDs according to the  
5 invention provide a new class of anti-inflammatory agent which provide the therapeutic benefits of NSAIDs while causing a much lower incidence of side-effects then typically observed with such agents.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318  
1319  
1320  
1321  
1322  
1323  
1324  
1325  
1326  
1327  
1328  
1329  
1330  
1331  
1332  
1333  
1334  
1335  
1336  
1337  
1338  
1339  
1340  
1341  
1342  
1343  
1344  
1345  
1346  
1347  
1348  
1349  
1350  
1351  
1352  
1353  
1354  
1355  
1356  
1357  
1358  
1359  
1360  
1361  
1362  
1363  
1364  
1365  
1366  
1367  
1368  
1369  
1370  
1371  
1372  
1373  
1374  
1375  
1376  
1377  
1378  
1379  
1380  
1381  
1382  
1383  
1384  
1385  
1386  
1387  
1388  
1389  
1390  
1391  
1392  
1393  
1394  
1395  
1396  
1397  
1398  
1399  
1400  
1401  
1402  
1403  
1404  
1405  
1406  
1407  
1408  
1409  
1410  
1411  
1412  
1413  
1414  
1415  
1416  
1417  
1418  
1419  
1420  
1421  
1422  
1423  
1424  
1425  
1426  
1427  
1428  
1429  
1430  
1431  
1432  
1433  
1434  
1435  
1436  
1437  
1438  
1439  
1440  
1441  
1442  
1443  
1444  
1445  
1446  
1447  
1448  
1449  
1450  
1451  
1452  
1453  
1454  
1455  
1456  
1457  
1458  
1459  
1460  
1461  
1462  
1463  
1464  
1465  
1466  
1467  
1468  
1469  
1470  
1471  
1472  
1473  
1474  
1475  
1476  
1477  
1478  
1479  
1480  
1481  
1482  
1483  
1484  
1485  
1486  
1487  
1488  
1489  
1490  
1491  
1492  
1493  
1494  
1495  
1496  
1497  
1498  
1499  
1500  
1501  
1502  
1503  
1504  
1505  
1506  
1507  
1508  
1509  
1510  
1511  
1512  
1513  
1514  
1515  
1516  
1517  
1518  
1519  
1520  
1521  
1522  
1523  
1524  
1525  
1526  
1527  
1528  
1529  
1530  
1531  
1532  
1533  
1534  
1535  
1536  
1537  
1538  
1539  
1540  
1541  
1542  
1543  
1544  
1545  
1546  
1547  
1548  
1549  
1550  
1551  
1552  
1553  
1554  
1555  
1556  
1557  
1558  
1559  
1560  
1561  
1562  
1563  
1564  
1565  
1566  
1567  
1568  
1569  
1570  
1571  
1572  
1573  
1574  
1575  
1576  
1577  
1578  
1579  
1580  
1581  
1582  
1583  
1584  
1585  
1586  
1587  
1588  
1589  
1590  
1591  
1592  
1593  
1594  
1595  
1596  
1597  
1598  
1599  
1600  
1601  
1602  
1603  
1604  
1605  
1606  
1607  
1608  
1609  
1610  
1611  
1612  
1613  
1614  
1615  
1616  
1617  
1618  
1619  
1620  
1621  
1622  
1623  
1624  
1625  
1626  
1627  
1628  
1629  
1630  
1631  
1632  
1633  
1634  
1635  
1636  
1637  
1638  
1639  
1640  
1641  
1642  
1643  
1644  
1645  
1646  
1647  
1648  
1649  
1650  
1651  
1652  
1653  
1654  
1655  
1656  
1657  
1658  
1659  
1660  
1661  
1662  
1663  
1664  
1665  
1666  
1667  
1668  
1669  
1670  
1671  
1672  
1673  
1674  
1675  
1676  
1677  
1678  
1679  
1680  
1681  
1682  
1683  
1684  
1685  
1686  
1687  
1688  
1689  
1690  
1691  
1692  
1693  
1694  
1695  
1696  
1697  
1698  
1699  
1700  
1701  
1702  
1703  
1704  
1705  
1706  
1707  
1708  
1709  
1710  
1711  
1712  
1713  
1714  
1715  
1716  
1717  
1718  
1719  
1720  
1721  
1722  
1723  
1724  
1725  
1726  
1727  
1728  
1729  
1730  
1731  
1732  
1733  
1734  
1735  
1736  
1737  
1738  
1739  
1740  
1741  
1742  
1743  
1744  
1745  
1746  
1747  
1748  
1749  
1750  
1751  
1752  
1753  
1754  
1755  
1756  
1757  
1758  
1759  
1760  
1761  
1762  
1763  
1764  
1765  
1766  
1767  
1768  
1769  
1770  
1771  
1772  
1773  
1774  
1775  
1776  
1777  
1778  
1779  
1780  
1781  
1782  
1783  
1784  
1785  
1786  
1787  
1788  
1789  
1790  
1791  
1792  
1793  
1794  
1795  
1796  
1797  
1798  
1799  
1800  
1801  
1802  
1803  
1804  
1805  
1806  
1807  
1808  
1809  
1810  
1811  
1812  
1813  
1814  
1815  
1816  
1817  
1818  
1819  
1820  
1821  
1822  
1823  
1824  
1825  
1826  
1827  
1828  
1829  
1830  
1831  
1832  
1833  
1834  
1835  
1836  
1837  
1838  
1839  
1840  
1841  
1842  
1843  
1844  
1845  
1846  
1847  
1848  
1849  
1850  
1851  
1852  
1853  
1854  
1855  
1856  
1857  
1858  
1859  
1860  
1861  
1862  
1863  
1864  
1865  
1866  
1867  
1868  
1869  
1870  
1871  
1872  
1873  
1874  
1875  
1876  
1877  
1878  
1879  
1880  
1881  
1882  
1883  
1884  
1885  
1886  
1887  
1888  
1889  
1890  
1891  
1892  
1893  
1894  
1895  
1896  
1897  
1898  
1899  
1900  
1901  
1902  
1903  
1904  
1905  
1906  
1907  
1908  
1909  
1910  
1911  
1912  
1913  
1914  
1915  
1916  
1917  
1918  
1919  
1920  
1921  
1922  
1923  
1924  
1925  
1926  
1927  
1928  
1929  
1930  
1931  
1932  
1933  
1934  
1935  
1936  
1937  
1938  
1939  
1940  
1941  
1942  
1943  
1944  
1945  
1946  
1947  
1948  
1949  
1950  
1951  
1952  
1953  
1954  
1955  
1956  
1957  
1958  
1959  
1960  
1961  
1962  
1963  
1964  
1965  
1966  
1967  
1968  
1969  
1970  
1971  
1972  
1973  
1974  
1975  
1976  
1977  
1978  
1979  
1980  
1981  
1982  
1983  
1984  
1985  
1986  
1987  
1988  
1989  
1990  
1991  
1992  
1993  
1994  
1995  
1996  
1997  
1998  
1999  
2000  
2001  
2002  
2003  
2004  
2005  
2006  
2007  
2008  
2009  
2010  
2011  
2012  
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2020  
2021  
2022  
2023  
2024  
2025  
2026  
2027  
2028  
2029  
2030  
2031  
2032  
2033  
2034  
2035  
2036  
2037  
2038  
2039  
2040  
2041  
2042  
2043  
2044  
2045  
2046  
2047  
2048  
2049  
2050  
2051  
2052  
2053  
2054  
2055  
2056  
2057  
2058  
2059  
2060  
2061  
2062  
2063  
2064  
2065  
2066  
2067  
2068  
2069  
2070  
2071  
2072  
2073  
2074  
2075  
2076  
2077  
2078  
2079  
2080  
2081  
2082  
2083  
2084  
2085  
2086  
2087  
2088  
2089  
2090  
2091  
2092  
2093  
2094  
2095  
2096  
2097  
2098  
2099  
2100  
2101  
2102  
2103  
2104  
2105  
2106  
2107  
2108  
2109  
2110  
2111  
2112  
2113  
2114  
2115  
2116  
2117  
2118  
2119  
2120  
2121  
2122  
2123  
2124  
2125  
2126  
2127  
2128  
2129  
2130  
2131  
2132  
2133  
2134  
2135  
2136  
2137  
2138  
2139  
2140  
2141  
2142  
2143  
2144  
2145  
2146  
2147  
2148  
2149  
2150  
2151  
2152  
2153  
2154  
2155  
2156  
2157  
2158  
2159  
2160  
2161  
2162  
2163  
2164  
2165  
2166  
2167  
2168  
2169  
2170  
2171  
2172  
2173  
2174  
2175  
2176  
2177  
2178  
2179  
2180  
2181  
2182  
2183  
2184  
2185  
2186  
2187  
2188  
2189  
2190  
2191  
2192  
2193  
2194  
2195  
2196  
2197  
2198  
2199  
2200  
2201  
2202  
2203  
2204  
2205  
2206  
2207  
2208  
2209  
2210  
2211  
2212  
2213  
2214  
2215  
2216  
2217




FIGURE 1




FIGURE 2

002250-03920960




FIGURE 3

DECLARATION FOR PATENT APPLICATION

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship is as stated below next to my name.

I believe that I am the original, first and joint inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled **PROTECTED FORMS OF PHARMACOLOGICALLY ACTIVE AGENTS AND USES THEREFOR**, the specification of which

  X   is attached hereto. (Attorney Docket No. MEDIN1400)  
  X   was filed on   June 23, 2000   as U.S. Application  
Serial No.                      and  
was amended on                      if applicable

**I hereby authorize and request insertion of the application serial number of the Application when officially known.**

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability of the subject matter of the Application as defined in Title 37, Code of Federal Regulations ("C.F.R."), § 1.56.

With respect to the Application, I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

\_\_\_\_\_  
(Application Serial No.)

\_\_\_\_\_  
(Filing Date)

With respect to the Application, I hereby claim the benefit under 35 U.S.C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of the application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability of the subject matter of the Application as defined in Title 37, C.F.R., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of the Application:

\_\_\_\_\_  
(Application Serial No.)

\_\_\_\_\_  
(Filing Date)

\_\_\_\_\_  
(Status)  
(patented, pending, abandoned)

\_\_\_\_\_  
(Application Serial No.)

\_\_\_\_\_  
(Filing Date)

\_\_\_\_\_  
(Status)  
(patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first inventor: Ching-San Lai

Inventor's signature: 

Date: 6/23/2000

Residence: Encinitas, California

Citizenship: United States

Post Office Address: 209 Lolita Street  
Encinitas, CA 92024

Full name of second inventor: Tingmin Wang

Inventor's signature: 

Date: 6/23/00

Residence: San Marcos, CA

Citizenship: People's Republic of China

Post Office Address: 585 Sonoma Street  
San Marcos, CA 92069

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Lai and Wang  
Application No.:  
Filed: June 23, 2000  
Title: PROTECTED FORMS OF A COMBINATION OF  
PHARMACOLOGICALLY ACTIVE AGENTS AND USES THEREFOR

POWER OF ATTORNEY BY ASSIGNEE

As a below-named assignee of the above-identified application ("Application"):

I hereby appoint the following attorneys of the assignee to prosecute the  
Application and to transact all business in the United States Patent and Trademark Office  
connected therewith:

JOSEPH R. BAKER	Registration No. 40,900
TIM ELLIS	Registration No. 41,734
LISA A. HAILE	Registration No. 38,347
WILLIAM N. HULSEY III,	Registration No. 33,402
RICHARD J. IMBRA	Registration No. 37,643
SHEILA R. KIRSCHENBAUM	Registration No. 44,835
JUNE M. LEARN	Registration No. 31,238
TIMOTHY W. LOHSE	Registration No. 35,255
TERRANCE A. MEADOR	Registration No. 30,298
JOHN OSKOREP	Registration No. 41,234
STEPHEN E. REITER	Registration No. 31,192
STEVEN R. SPRINKLE	Registration No. 40,825
RAMSEY R. STEWART	Registration No. 38,322
DAVID R. STEVENS	Registration No. 38,626
BARRY N. YOUNG	Registration No. 27,744



Applicant: Lai and Wang  
Application No.:  
Filed: June 23, 2000  
Page 2

**I hereby authorize and request insertion of the application number of the  
Application when officially known.**

Direct all telephone calls to:

STEPHEN E. REITER  
Telephone: (858) 677-1409

Address all correspondence to:

STEPHEN E. REITER  
GRAY CARY WARE & FREIDENRICH LLP  
4365 Executive Drive, Suite 1600  
San Diego, CA 92121

MEDINOX, INC., a corporation of the state of California.

By: 

Name: Ching-San Lai

Title: President and Chief Executive Officer

Date: 6/23/2000